<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015635</url>
  </required_header>
  <id_info>
    <org_study_id>300798-01</org_study_id>
    <nct_id>NCT04015635</nct_id>
  </id_info>
  <brief_title>The Role of the Immune and Inflammatory Systems in Hypertension</brief_title>
  <official_title>A Study of the Roles of the Immune and Inflammatory Systems in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To define the cytokine and cellular immune signature of primary hypertension. Cross sectional
      clinical/laboratory study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental data show the presence of immune and inflammatory systems dysregulation in
      hypertension. Understanding of the inflammatory and immune nature of hypertension is
      currently based on studies in rodent models of hypertension, but is supported by human
      epidemiological and genome wide association studies (GWAS) studies. It is now essential to
      identify key checkpoints and inflammatory mechanism(s) involved in human hypertension in
      comprehensive and sufficiently powered studies, which will then be able to guide subsequent
      in-depth hypothesis-driven mechanistic studies. This approach may provide the basis for
      future randomized clinical trials (RCTs).

      To define the relationships and predictive value of the immune signature of hypertension and
      clinical phenotypes of hypertension :

        -  Predictive value of immune signature for blood pressure parameters measured by
           ambulatory blood pressure measurements (ABPM)

        -  Predictive value of immune signature for endothelial function assessed by Endo-PAT2000
           and flow mediated dilatation (FMD) both complementary non-invasive techniques.

        -  Predictive value of immune signature for vascular stiffness and central pressure
           assessed by SphygmoCor

        -  Predictive value of immune signature for renal function parameters

        -  Predictive value of immune signature for cognitive function. To define genetic
           determinants of immune signature of hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cellular immune signature of primary hypertension: flow cytometry quantification of peripheral blood monocyte subtypes</measure>
    <time_frame>rolling analysis until total number recruited or end of study period (June 2021)</time_frame>
    <description>measuring expression of B cells markers, T cell markers, and DC cell markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>demographics: blood pressure</measure>
    <time_frame>rolling analysis until total number recruited or end of study period (June 2021)</time_frame>
    <description>systolic and diastolic; office and ambulatory; in mmHG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>demographics: BMI</measure>
    <time_frame>rolling analysis until total number recruited or end of study period (June 2021)</time_frame>
    <description>in kg/m^2; calculated from height in meters and weight in kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endo-PAT2000 &quot;hyperaemia index&quot;</measure>
    <time_frame>until total number recruited or end of study period (June 2021)</time_frame>
    <description>As a measure of endothelial function: measuring Peripheral Arterial Tone (PAT) signal changes to a reactive hyperemia challenge. The PAT signal is a measure of the digital pulsatile volume. The expected response is of a post occlusion increase of the PAT signal amplitude. PAT score is provided automatically by the system's software and is basically the ratio between the post- to pre- occlusion average signal size, corrected for systemic changes and baseline level.
changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>flow mediated dilatation (FMD) (percent)</measure>
    <time_frame>until total number recruited or end of study period (June 2021)</time_frame>
    <description>as a measure of endothelial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid intimal media thickness (mm)</measure>
    <time_frame>until total number recruited or end of study period (June 2021)</time_frame>
    <description>measure of vascular stiffness and central pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessed by SphygmoCor (meters/second)</measure>
    <time_frame>until total number recruited or end of study period (June 2021)</time_frame>
    <description>measure of vascular stiffness and central pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Creatinine (mMol/L)</measure>
    <time_frame>until total number recruited or end of study period (June 2021)</time_frame>
    <description>measure of renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;International Physical Activity Questionnaire&quot; (score)</measure>
    <time_frame>until end of study period (June 2021)</time_frame>
    <description>Questionnaire measures of physical activity. From hours of sedentary time, mild/moderate/vigorous activity over a week, it then calculates METs/week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interheart Diet Questionnaire score</measure>
    <time_frame>until end of study period (June 2021)</time_frame>
    <description>Questionnaire measures of health and activity. Based on known risk factors ie smoking diabetes, family history, dietary factors. Used as a validated measure of cardiovascular risk; score from 0 (minimal risk) to 48 (high risk)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypertension</condition>
  <condition>Inflammation</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>120 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
Clinical and laboratory assessment. NO intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>120 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
Clinical and laboratory assessment. NO intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None involved</intervention_name>
    <description>NO intervention</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for flow cytometry. Blood and urine for biomarker analysis. Blood for possible RNA
      analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Otherwise fit and healthy individuals with hypertension who are treatment naive.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-50 years

          -  Cases: Office blood pressure ≥140 and ≥90

          -  Controls: Office blood pressure &lt;140 and &lt;90 and age, sex and BMI matching to cases

        Exclusion Criteria:

          -  Age &gt;50 years old;

          -  Secondary hypertension (including e.g. adrenal tumours, pheochromocytoma, renal artery
             stenosis; thyroid disease)

          -  Acute inflammatory disorders incl. flu, rhinitis, sinusitis etc. within 3 weeks;

          -  hospitalization within the past 3 months;

          -  Life expectancy of &lt; 3 years;

          -  History of alcohol/substance abuse

          -  Inflammatory conditions e.g. Allergic disorders; chronic infections, COPD,
             tuberculosis; hepatitis B or C; pneumonitis, bronchiectasis; pericardial or pleural
             effusion, ascites; liver disease;

          -  Chronic inflammatory/autoimmune conditions such (e.g. SLE, rheumatoid arthritis,
             ulcerative colitis/Crohn's disease; non-basal cell malignancy or myelo- or
             lymphoproliferative disease within the past 5 years; known HIV+; Immunizations (3
             months); pulmonary hypertension;

          -  Pregnancy, nursing;

          -  History of symptomatic coronary artery disease (events) or heart failure;

          -  BMI&gt;35,

          -  diabetes/glucose intolerance (fasting glucose, HbA1; testing, glucose challenge where
             indicated);

          -  Known albuminuria/microalbuminuria;

          -  GFR&lt;60mL/min/1.73m2.

          -  Any chronic concurrent treatment: Use of systemic or local steroids/immunosuppressive
             agents (within 6 months) of the inclusion; Current (within past 3 months) use of
             anti-hypertensive medication;

          -  Major depressive illness or other psychiatric conditions.

          -  Participants who decline participation in the study or who are unable to provide
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eleanor Murray, MBChB</last_name>
    <phone>0141 232 7600</phone>
    <email>cams-ins-inflammatension@glasgow.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <state>City Of Glasgow</state>
        <zip>G51 4LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tomasz guzik</last_name>
      <phone>0141 3307590</phone>
      <email>cams-ins-inflammatension@glasgow.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Flynn</last_name>
      <phone>0141 232 7600</phone>
      <email>joanne.flynn@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>eleanor c murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Eleanor Murray</investigator_full_name>
    <investigator_title>Prinicipal Investigator; Doctor; Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>blood pressure</keyword>
  <keyword>hypertension</keyword>
  <keyword>inflammation</keyword>
  <keyword>immune dysfunction</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT04015635/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

